Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis
Laboratory studyOther animalsWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Female Wistar albino rats with surgically induced endometriosis (10 per group)
- Dose used in the study
- Co-micronised PEA/polydatin 10 mg/kg/day, oral
- Duration
- 28 days
- What was measured
- Endometrioma volume, fibrosis, mast cell number, VEGF, nerve growth factor, ICAM, matrix metalloproteinase-9, lymphocyte accumulation, and oxidative/inflammatory markers
What the authors reported
Treated rats had smaller endometriotic cyst diameter, better fibrosis scores and fewer mast cells. PEA/polydatin reduced VEGF, nerve growth factor, ICAM and MMP-9 expression, lymphocyte accumulation, peroxynitrite formation, PARP activation and NF-kB nuclear translocation.
Limits of this study
A rat model of surgically induced endometriosis; it cannot show effect in people. Funding and conflicts not stated in the abstract; the group has used Epitech-linked co-micronised PEA formulations before.
Source
PubMed 27790149 · doi:10.3389/fphar.2016.00382
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.